Exagen Inc. (XGN) Stock Price & Analysis
Exagen Inc. (XGN) fell 5.45% to USD 4.68 as of July 25, 2026 at 10:26 UTC, according to Nexqual real-time market data.
XGN last closed at USD 4.95; the session ranged USD 4.65–5.11 on volume of 186,983 shares. Market capitalization is $113.07M, with a 52-week range of USD 2.59–12.23 (NGM). Source: Nexqual, July 25, 2026 at 10:26 UTC.
Key Statistics (as of July 25, 2026 at 10:26 UTC)
| Price | USD 4.68 |
|---|---|
| Change | ▼ 5.45% (down) |
| Previous Close | USD 4.95 |
| Open | USD 5 |
| Day Range | USD 4.65 – 5.11 |
| 52-Week Range | USD 2.59 – 12.23 |
| Volume | 186,983 shares |
| Market Cap | $113.07M |
| Exchange | NGM |
Technical Analysis (XGN)
Nexqual's technical model rates XGN "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 10:26 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 53.72 (neutral) |
| vs SMA50 | Above (USD 4.46) |
| MACD | 0.1 (positive) |
Analyst Ratings (XGN)
Wall Street analysts rate XGN "Strong Buy" based on 7 analysts, with a mean price target of USD 8.57 (range USD 8–10), per Nexqual as of July 25, 2026 at 10:26 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 8.57 |
| High Target | USD 10 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (XGN)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -0.17 |
| Revenue Estimate | $17.87M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.2 vs est -0.25 ▲ beat |
| 2025-12-31 | USD -0.27 vs est -0.19 ▼ miss |
| 2025-09-30 | USD -0.31 vs est -0.16 ▼ miss |
| 2025-06-30 | USD -0.18 vs est -0.15 ▼ miss |
Source: Nexqual, July 25, 2026 at 10:26 UTC.
Financials & Fundamentals (XGN)
| Total Revenue | $68.38M |
|---|---|
| Revenue Growth (YoY) | +11.70% |
| Gross Margin | +58.32% |
| Operating Margin | -19.73% |
| Profit Margin | -29.49% |
| ROE | -193.58% |
| Debt / Equity | 188.1 |
| Current Ratio | 3.47 |
| Total Cash | $21.51M |
| Total Debt | $27.15M |
| Free Cash Flow | $-9.07M |
Source: Nexqual, July 25, 2026 at 10:26 UTC.
Financial Health Score (XGN)
Nexqual rates Exagen Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 10:26 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 58%, operating -20% |
| Balance Sheet | Weak — $22M cash vs $27M debt |
| Cash Flow | Weak — FCF negative: -$9M, burning cash |
| Efficiency | Critical — ROE -194%, ROA -19.1% |
Ownership (XGN)
| Insider Ownership | +27.91% |
|---|---|
| Institutional Ownership | +55.28% |
| Shares Outstanding | 24.16M |
| Float | 13.81M |
| Short % of Float | +4.47% |
Source: Nexqual, July 25, 2026 at 10:26 UTC.
Leadership (XGN)
Exagen Inc. is led by John Aballi (age 40), CEO, President & Director, per Nexqual as of July 25, 2026 at 10:26 UTC.
| CEO, President & Director | John Aballi (age 40) |
|---|---|
| Executive Chairman of the Board of Directors | Tina S. Nova (age 71) |
| CFO & Corporate Secretary | Jeffrey G. Black (age 56) |
| Chief Scientific Officer | Michael Mahler |
| Vice President of Investor Relations | Tina Jacobsen |
Major Backers & Investors (XGN)
Notable institutional backers of Exagen Inc. include Balyasny Asset Management LP, Wexford Capital LP, Acadian Asset Management. LLC, according to Nexqual as of July 25, 2026 at 10:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Balyasny Asset Management LP | 3.3% |
| Wexford Capital LP | 3.28% |
| Acadian Asset Management. LLC | 2.85% |
| Nano Cap New Millennium Growth Fund L P | 2.42% |
| Silvercrest Asset Management Group, LLC | 2.23% |
| Kennedy Capital Management, LLC | 2.04% |
| FourWorld Capital Management, LLC | 1.82% |
| RTW Investments LP | 1.64% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.58% |
Source: Nexqual, July 25, 2026 at 10:26 UTC.
From Exagen Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- Our laboratory is certified for performance of high-complexity testing by the Centers for Medicare & Medicaid Services (CMS) in accordance with CLIA and is licensed by California and all states requiring out-of-state licensure, including the New York Department of Health (NYSDOH).
- The research projects we support are those that we believe will have a competitive advantage (such as using proprietary technology), a pathway for reimbursement and an established evidence development plan with sufficient market size.
- Our Proprietary Technologies We believe the competitive advantage for our testing products is supported by two core proprietary technologies: our AVISE ® Lupus platform, which incorporate Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE and a set of three biomarkers, the t-cell based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into our AVISE ® CTD product.
- We believe the availability of complement biomarkers combined with our proprietary algorithmic interpretations, as a support or replacement of standard C3 and C4 measures, is of great value for rheumatologists and their patients.
Partnerships
- We believe there is significant potential to capitalize on our proprietary technologies by integrating with commercially validated biomarkers to develop testing products with superior clinical utility, on our own or through collaboration with partners.
- We believe there is significant potential to enhance existing or develop new testing products with superior clinical utility, on our own or through collaboration with partners. ▪ Lupus Nephritis (LN) Biomarkers .
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TELA | TELA Bio, Inc. | USD 0.69 | ▼ 5.73% |
| APYX | Apyx Medical Corporation | USD 3.92 | ▲ 0.26% |
| VRCA | Verrica Pharmaceuticals Inc. | USD 5.02 | ▼ 11.93% |
| BDSX | Biodesix, Inc. | USD 22 | ▲ 2.85% |
| FULC | Fulcrum Therapeutics, Inc. | USD 3.72 | ▲ 0.54% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 10:26 UTC. This page is informational and not investment advice.